The move comes as part of a competition law investigation by the Competition and Markets Authority (CMA) into drug firms King Pharmaceuticals Limited, Alissa Healthcare Research Limited and Lexon (UK) Limited.
In June 2019, the CMA issued a statement of objections provisionally finding that the 3 suppliers had exchanged commercially sensitive information about prices, volumes and entry plans in order to keep prices up.
Nortriptyline is prescribed by the NHS and relied on by thousands of patients every month to relieve the symptoms of depression. NHS spending on the drug peaked at £38 million in 2015.
Full Content: Gov UK
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
